Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...
Zacks Investment Research on MSN
AGEN vs. IOVA: Which cancer biotech stock has more upside potential?
Both Agenus AGEN and Iovance Biotherapeutics IOVA are small-cap companies focused on next-generation cancer immunotherapies ...
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the ...
Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.
When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare ...
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...
In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...
Natera gets a buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue ...
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results